The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Subscribe To Our Newsletter & Stay Updated
